E U R O P E A N C A R D I O L O G Y R E V I E W
Chile and Brazil, and in large areas of Argentina and Venezuela, achieving an average reduction in prevalence and incidence of 70%.
Chagas disease is an important cause of dilated cardiomyopathy in
Latin America, where the disease is endemic. 15, 16 Chagas heart disease (ChHD) commonly presents with symptomatic ventricular arrhythmias, symptomatic bradyarrhythmias, sudden death, HF, embolic events, chest pain and high susceptibility to proarrhythmia. 15 The clinical picture mimics that of coronary artery disease and idiopathic dilated cardiomyopathy. The prognosis is poor for patients with malignant ventricular arrhythmias, HF, left ventricular aneurysm or global systolic dysfunction. 16 Moreover, in an Argentinian survey, HF was the most frequent finding, leading clinicians to suspect Chagas disease. 17 HF may occur in approximately 10% of subjects who have Chagas disease with cardiac involvement. 18, 19 A meta-analysis of 143 studies of HF from Latin America reported the incidence of HF in Chagas disease to be 137 per 100,000 people per year and annual mortality to be 1.12-7.18 per 100,000 people per year. Higher in-hospital mortality was also found in patients with Chagas disease, compared with a nonChagas disease aetiology, representing 36% of the aetiology of HF. 20 The estimated prevalence of Chagas disease within HF populations in Argentina is about 15%. 21 However, data from different surveys reveal a Chagas disease prevalence of 4.0-6.0% in outpatient registries and 1.3-8.4% in decompensated HF settings in Argentina, and of 0.6-20.0%
in Latin American registries. [22] [23] [24] This discrepancy may be attributable to actual lower prevalence, underrepresentation of rural inhabitants in the surveys, low use of screening tests or because some cases of Chagas disease might represent a comorbidity. The Grupo de Estudio de la Sobrevida en la Insuficiencia Cardíaca en Argentina (GESICA) Registry has shown a prevalence of true ChCM of 6.4%. 25 Patients with Chagas disease had a different clinical profile from, and were treated differently to, those without Chagas disease. Patients with ChCM were admitted more frequently for decompensated HF than other patients. 26 It has been reported that long-term outcomes in patients with chronic systolic HF secondary to ChCM are poorer than those in patients with idiopathic and ischaemic aetiologies. 27, 28 Acute decompensated HF (ADHF) is a common clinical condition in ChCM. A study has shown that patients with ChCM had the highest proportion of hospital admissions for cardiogenic shock and arrhythmia, with lower systolic blood pressure and a higher proportion of right ventricular HF than other aetiologies. 29 Outcomes were also influenced by aetiology, and ChCM had the lowest proportion of hospital discharge and the highest proportion of cardiac transplant when compared with other aetiologies, mainly in Latin American countries. So, the poorer prognosis of ChCM in comparison with other common causes of cardiomyopathy is also applicable to vulnerable ADHF, related to the severity of presentation and other issues, including socioeconomic factors.
Typically, the clinical profile of ChCM includes younger people, more often women, with lower prevalence of hypertension, diabetes and renal impairment, compared with non-ChCM patients. In contrast,
health-related quality of life was worse and the prevalence of stroke and pacemaker implantation were higher in ChCM compared with non-ChCM aetiologies. Despite these differences, the rates of cardiovascular death, HF hospitalisation and all-cause mortality were higher in patients with Chagas disease than other non-ischaemic and ischaemic patients.
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Main Pathophysiologic Pathways
Chagas disease may be diagnosed in the infected patient in either acute or chronic clinical presentation. In some cases, the acute phase is light and can go undiagnosed by the patient and the medical team. Heart Failure, Arrhythmias and Cardiomyopathies 
ECG and Holter monitor
The Enlargement of all four cardiac chambers with or without signs of pulmonary congestion suggests ChCM. 41 X-ray is also useful in the diagnosis of megacolon and megaoesophagus, which can be corroborated with endoscopy.
Parasitaemia
In the acute phase of Chagas disease, parasitaemia can be observed with a microscopic blood examination. 49 Microhaematocrit is a widely used method of identifying congenital infection. The trypomastigotes present in the blood can be seen during the first 8-12 weeks and, after that, parasitaemia falls below detectable levels. 50 
Serology and C-reactive Protein
Indirect immunofluorescence, haemagglutination, and enzyme-linked immunosorbent assays are commonly used in screening for Chagas disease. [51] [52] [53] The WHO recommends diagnosing Chagas disease with two conventional laboratory tests and doing a third test in cases of discordance. C-reactive protein testing is the most sensitive test in acute infection or reactivation in patients with Chagas disease who are organ recipients or are otherwise immunocompromised.
54-56

Echocardiography
Echocardiography may find segmental wall motion abnormalities, including akinesia, hypokinesia or dyskinesia with preserved septal contraction, left ventricular aneurysm (most common in apex), left ventricular diastolic dysfunction, dilated cardiomyopathy involving both ventricles, and mural thrombus, mitral and tricuspid regurgitation.
Assessment of myocardial strain through speckle tracking could help to detect myocardial damage in early periods of the disease, and some authors describe decreased global radial strain during the indeterminate stage, even in patients with a normal ECG and common echocardiogram. [57] [58] [59] Left ventricular global dysfunction with low ejection fraction is one of the most important predictors of death in ChCM. The presence of chest pain -mostly non-typical angina pectoris -in patients with Chagas disease could be attributable to microvascular perfusion abnormalities.
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Cardiac MRI
Cardiac MRI with or without gadolinium is useful to obtain more precise information about left ventricular ejection fraction and right ventricular ejection fraction, thrombus and fibrosis, giving us a good diagnostic and prognostic base. 
Specific Antitrypanosomal Therapy
Treatment for Chagas disease is mainly non-invasive in the early stages, when nifurtimox or benznidazole are used. More invasive procedures could be applied in advanced stages of the pathology, for example, where there is pericardial effusion, cardiac tamponade, arrhythmia and HF.
Benznidazole is a nitroimidazole with antiparasitic effects. The sideeffects include rash, numbness, fever, muscle pain, anorexia and weight Heart Failure, Arrhythmias and Cardiomyopathies
loss, nausea, vomiting and insomnia, plus a rare but important symptom, bone marrow suppression, which can lead to low blood cell levels.
Nifurtimox forms a nitro-anion radical metabolite that reacts with parasite nucleic acids causing significant DNA breakdown. It is used as a second specific treatment option in early Chagas disease because it has more serious side-effects than benznidazole, including anorexia, weight loss, nausea, vomiting, headache, dizziness, amnesia, rash, depression, anxiety, confusion, fever, sore throat, chills, seizures, impotence, tremors, muscle weakness and numbness.
Invasive Treatment of Gastrointestinal Chagas Disease
Invasive procedures to treat megacolon and megaoesophagus may be necessary. Megacolon can be treated with the Duhamel procedure or a modified version of the procedure, introduced by Haddad.
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Laparoscopic procedures could also be applied. Megaoesophagus can be treated with wide oesophago-cardiomyectomy on the anterior oesophagogastric junction, combined with an antireflux valvuloplasty procedure or oesophagogastroplasty through the oesophageal bed. 89 These procedures could be extremely useful when advanced stages of HF are present and it is necessary to offer more invasive procedures.
Invasive Treatment of Cardiovascular Chagas Disease
Cardiac manifestations of Chagas disease may also need invasive 
Automatic ICDs
Malignant ventricular arrhythmia and SCD are more frequent in patients with Chagas disease. 91, 95, 96 Automatic ICDs may be used in the treatment of severe arrhythmias with high risk of SCD. 97 Primary or secondary prevention should be a routine indication for patients with Chagas disease with malignant arrhythmias. 98 The combination of ablation procedures, amiodarone and/or beta-blockers might be considered in special cases to reduce the number of automatic ICD therapies, as in other types of cardiomyopathy. 99 
Ablation Therapy
Ablation ventricular tachycardia therapy should be considered after oral medication failure. 100 CRT could be used in the treatment of patients with severe HF and left bundle branch block but there is scarce evidence to support resynchronisation therapy for patients with ChCM and right bundle branch block or its combination with left anterior fascicular block, where experience is not conclusive.
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Ambulatory Pulmonary Pressure Monitoring
Other less invasive procedures such as ambulatory pulmonary pressure monitoring, which are useful in patients with HF, need to be tested in patients with Chagas disease HF and could probably prevent recurrent episodes of decompensation. 75, 77 Heart Transplant Heart transplantation and left ventricular assist devices (LVAD) have an important place in the treatment of irreversible HF in patients with Chagas disease.
Chagas disease was initially considered a contraindication for transplant because of the possible reactivation after transplantation and immunosuppression, but advances in immunosuppression programmes since the 1990s mean that there is now a similar survival and quality of life in HF patients with Chagas cardiomyopathy. 
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Circulatory Assist Devices Different devices for cardiac assist could be used in patients with endstage HF as a result of Chagas disease. These could be applied as a bridge to transplant, a bridge to recovery during the acute period or as a bridge to decision, or even as destination therapy depending on the general state of the patient and meticulous clinical evaluation of the possibility of survival and better quality of life. [107] [108] [109] [110] As in the transplant population, previous evaluation of the pulmonary pressures plus poor right ventricular function could be a contraindication for LVAD alone.
Global Action on Chagas Disease
ChHD is a preventable non-communicable disease (NCD) that mainly affects the poorest and most vulnerable populations of South America.
Driven by poverty, poor access to health services and other health system weaknesses, the majority of people with this condition live in low-and middle-income countries.
The need for concerted global action to control NCDs is a high priority on the global health agenda. This is evident in the UN political declarations on the prevention and control of NCDs -the 25×25 target aims for a 25% reduction in premature mortality from NCDs Chagas Disease and Heart Failure 
Conclusion
Chagas disease -originally a South American endemic health problemis expanding worldwide as a result of people migrating. The pathology of Chagas disease is based in an inmunoinflammatory reaction producing fibrosis and remodelling, mainly in the myocardium. In many cases these mechanisms result in a dilated cardiomyopathy with HF and reduced ejection fraction, frequent cardiac arrhythmias and different types of heart block. The diagnosis and treatment of HF as a result of Chagas disease include the usual steps for other aetiologies, plus the need for laboratory techniques for parasite-related issues. International scientific organisations are concerned about this health problem and about delivering recommendations for prevention and early diagnosis.
